The estimated Net Worth of Michael F Cola is at least $2.46 Milhão dollars as of 9 June 2020. Mr. Cola owns over 100,000 units of Sage Therapeutics Inc stock worth over $1,316,338 and over the last 21 years he sold SAGE stock worth over $0. In addition, he makes $1,147,300 as Independent Director at Sage Therapeutics Inc.
Michael has made over 4 trades of the Sage Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of SAGE stock worth $250,000 on 9 June 2020.
The largest trade he's ever made was buying 2,049,376 units of Sage Therapeutics Inc stock on 5 December 2019 worth over $266,419. On average, Michael trades about 52,982 units every 22 days since 2004. As of 9 June 2020 he still owns at least 175,746 units of Sage Therapeutics Inc stock.
You can see the complete history of Mr. Cola stock trades at the bottom of the page.
Michael F. Cola serves as Independent Director of the Company. He currently serves as Chief Executive Officer of Cerecor, Inc., or Cerecor, formerly Aevi Genomic Medicine, Inc., or Aevi, a position he has held since February 2020, when Cerecor acquired Aevi. Prior to joining Cerecor, Mr. Cola served as President and Chief Executive Officer of Aevi since 2013. From 2005 to 2012, he served as president of specialty pharmaceuticals at Shire. Previously, from 2000 to 2005, Mr. Cola also served as a Growth Capital Provider and President of the life sciences group for Safeguard Scientifics, Inc., where he served as Chairman and Chief Executive Officer of Clarient, Inc., and Chairman of Laureate Pharma, Inc. In addition, Mr. Cola has held senior positions in product development and commercialization at Astra Merck Inc. and AstraZeneca plc. Additionally, in the past five years, Mr. Cola has served on the board of directors of Vanda Pharmaceuticals Inc., Phathom Pharmaceuticals, Inc., Nupathe Inc. and as chairman for the board of governors of the Boys & Girls Clubs of Philadelphia. Mr. Cola received a B.A. in biology and physics from Ursinus College and an M.S. in biomedical science from Drexel University.
As the Independent Director of Sage Therapeutics Inc, the total compensation of Michael Cola at Sage Therapeutics Inc is $1,147,300. There are 10 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
Michael Cola is 60, he's been the Independent Director of Sage Therapeutics Inc since 2014. There are 2 older and 14 younger executives at Sage Therapeutics Inc. The oldest executive at Sage Therapeutics Inc is Dr. Jeffrey M. Jonas, 68, who is the Chief Innovation Officer, Chair of the Science & Technology Forum and Director.
Michael's mailing address filed with the SEC is C/O SAGE THERAPEUTICS, INC., 215 FIRST STREET, CAMBRIDGE, MA, 02142.
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen, eMichael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Sage Therapeutics Inc executives and other stock owners filed with the SEC include: